Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
HeartFlow, Inc. is a privately held medical technology company that develops non-invasive, software-based solutions for the diagnosis and management of coronary artery disease (CAD). The company operates within the digital health, medical imaging, and cardiovascular diagnostics industries, with a primary focus on applying advanced computational modeling and artificial intelligence to cardiac CT imaging. Its core product enables clinicians to assess coronary physiology without the need for invasive procedures.
The company’s primary revenue driver is its flagship technology, HeartFlow FFRCT Analysis, a cloud-based service that uses coronary computed tomography angiography (CCTA) images to create patient-specific 3D models of the coronary arteries and calculate fractional flow reserve. HeartFlow serves hospitals, imaging centers, and cardiology practices, positioning itself as a clinically validated alternative to invasive diagnostic angiography. Founded in 2007, HeartFlow evolved from academic research in computational fluid dynamics and has progressively transitioned from R&D to commercial-scale clinical adoption following regulatory clearances and growing reimbursement coverage in major healthcare markets.
Business Operations
HeartFlow generates revenue through the provision of its proprietary software-as-a-service diagnostic analyses, which are ordered by clinicians and delivered via a secure cloud platform. The company operates primarily as a technology and analytics provider rather than a device manufacturer, controlling its core intellectual property related to AI-driven image segmentation, physiological modeling, and cloud-based computational infrastructure.
Commercial operations are concentrated in the United States and select international markets, supported by clinical, sales, and customer support teams. HeartFlow maintains subsidiaries in international jurisdictions to support regulatory, sales, and operational needs, including HeartFlow International B.V. The company collaborates with imaging hardware vendors, healthcare systems, and academic institutions, though details of specific long-term joint ventures are limited in public disclosures. Data inconclusive based on available public sources regarding the financial contribution of individual partnerships.
Strategic Position & Investments
HeartFlow’s strategic direction centers on expanding the clinical utility of non-invasive cardiac diagnostics and increasing adoption of CCTA as a frontline test for CAD. Growth initiatives include expanding payer reimbursement coverage, deepening penetration in U.S. hospital systems, and extending product capabilities into broader coronary disease planning and precision medicine applications.
The company has completed multiple private funding rounds backed by institutional investors and strategic healthcare funds, which have been used to support product development, clinical trials, and global commercialization. HeartFlow has invested heavily in AI-driven imaging analytics and next-generation computational models, positioning itself at the intersection of artificial intelligence and cardiovascular care. No material acquisitions have been conclusively verified through public filings; data inconclusive based on available public sources.
Geographic Footprint
HeartFlow is headquartered in Mountain View, California, and maintains its primary operational presence in North America. The company has expanded commercially into Europe and parts of Asia-Pacific, supported by regional subsidiaries and distributor relationships.
International influence is primarily driven by regulatory approvals, clinical guideline inclusion, and reimbursement progress in individual countries. While HeartFlow reports a growing global customer base, detailed revenue breakdowns by region are not publicly disclosed. Data inconclusive based on available public sources regarding precise international revenue distribution.
Leadership & Governance
HeartFlow was founded by academic and industry leaders in biomedical engineering and cardiovascular research, with governance shaped by venture-backed growth and clinical evidence generation. The leadership team emphasizes a strategy focused on evidence-based medicine, regulatory rigor, and integration into standard cardiac care pathways.
Key executives include:
- Campbell Rogers – Chief Executive Officer
- John Stevens – Chief Financial Officer
- Devin Patel – Chief Commercial Officer
- Sanjiv Kaul – Chief Medical Officer
- William Lombardi – Chief Medical Officer, Interventional Cardiology
The company’s governance structure includes an independent board with representation from major institutional investors and healthcare industry veterans, reflecting a strategic vision centered on long-term clinical adoption and scalable global growth.